Circular Genomics Appoints World-Renowned Expert Dr. Henrik Zetterberg to Scientific Advisory Board
On April 24, 2026, Circular Genomics announced the appointment of Dr. Henrik Zetterberg, a leading authority in neurochemistry and Alzheimer’s disease biomarkers, to its Scientific Advisory Board. This strategic move strengthens the company’s mission to advance blood-based circular RNA (circRNA) biomarkers for neurodegenerative diseases.
Who is Dr. Henrik Zetterberg?
Dr. Henrik Zetterberg is Professor of Neurochemistry at the University of Gothenburg, Sweden, University of Wisconsin-Madison, and University College London (UCL), UK. He leads the UK Dementia Research Institute Fluid Biomarker Laboratory at UCL and serves as Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg.
Dr. Zetterberg is widely recognized as one of the world’s foremost authorities on fluid biomarkers for neurodegenerative diseases. His research has been instrumental in establishing blood-based biomarkers—including neurofilament light chain (NfL), phosphorylated tau (p-tau 217), GFAP, and amyloid-beta—as non-invasive tools for detecting and staging Alzheimer’s disease and other neurodegenerative disorders.
Why This Appointment Matters for Circular Genomics
Circular Genomics is a biotechnology company revolutionizing neurological and psychiatric precision medicine through brain-derived circular RNA (circRNA) biomarkers. The company is actively developing circRNA blood-based assays for Alzheimer’s disease diagnosis and risk prediction.
Dr. Zetterberg’s expertise in Alzheimer’s fluid biomarkers directly supports Circular Genomics’ efforts to advance its platform. His appointment brings valuable insights into biomarker validation and clinical translation, which are critical for the company’s goal of making brain disorders measurable and manageable.
About Circular Genomics’ Mission
The company collaborates with leading institutions including Washington University in St. Louis and has recently finalized exclusive IP licenses with global research institutions to advance its Alzheimer’s disease blood test. By focusing on circRNA biomarkers, Circular Genomics aims to provide earlier and more accurate detection of neurodegenerative conditions through simple blood tests.
Key Takeaways
- Dr. Henrik Zetterberg joins Circular Genomics’ Scientific Advisory Board as a world-renowned expert in neurochemistry and Alzheimer’s biomarkers.
- His appointment enhances the company’s ability to develop and validate blood-based circRNA biomarkers for neurodegenerative diseases.
- Circular Genomics is advancing Alzheimer’s disease diagnosis through innovative circRNA technology, with Dr. Zetterberg’s expertise supporting biomarker validation and clinical application.
Frequently Asked Questions
What are circular RNA (circRNA) biomarkers?
Circular RNA (circRNA) biomarkers are a type of RNA molecule that forms a closed loop structure. Brain-derived circRNAs have shown promise as stable, detectable signals in blood that reflect neurological processes, offering potential for non-invasive diagnosis of brain disorders.
How do blood-based biomarkers help in Alzheimer’s disease?
Blood-based biomarkers, such as those Dr. Zetterberg has helped establish (like NfL and p-tau 217), allow for less invasive, more accessible testing compared to cerebrospinal fluid analysis or PET scans. They enable earlier detection, tracking of disease progression, and differentiation from other neurodegenerative conditions.
What is Circular Genomics’ focus?
Circular Genomics focuses on developing brain-derived circular RNA biomarkers for neurological and psychiatric precision medicine, aiming to make brain disorders measurable through blood-based tests.